Castle Biosciences Shares Up 54.6% as 2026 Loss Estimates Narrow to $0.96
Castle Biosciences holds a top-tier strong-buy analyst rating and has seen analysts’ loss-per-share forecasts for fiscal 2026 tighten from $1.06 to $0.96. Its shares have climbed 54.6% over the past six months, and its earnings have beaten estimates in three of the last four quarters by an average of 66.11%.
1. Share Performance
Castle Biosciences’ stock has rallied 54.6% over the past six months, outperforming the broader biotech sector. This surge reflects growing investor confidence in its pipeline progress and improved financial outlook.
2. Analyst Estimate Revisions
Analysts have revised Castle’s 2026 loss-per-share forecast from $1.06 to $0.96 over the past 60 days, indicating greater optimism about cost management and revenue prospects. The tightening estimate suggests expectations of lower operating losses next year.
3. Earnings Surprise Record and Rating
The company has beaten earnings estimates in three of the last four quarters, delivering an average surprise of 66.11%. Castle holds a top-tier strong-buy analyst rating, underlining confidence in its growth trajectory and clinical development milestones.